{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'b)', 'Use of reliever medication (ie, albuterol/salbutamol', 'or levalbuterol/levosalbutamol), other than as a', 'preventive for exercise induced bronchospasm, on', '3 or more days per week, on at least one week', 'during the Screening Period.', 'c)', 'Sleep awakening due to asthma symptoms', 'requiring use of reliever medication at least once', 'during the Screening Period.', 'd)', 'Asthma symptoms 3 or more days per week on at', 'least one week during the Screening Period.', 'Exclusion Criteria:', 'E 01.', 'Patients <6 or >12 years of age.', 'E 02.', 'Patients <16 kg body weight (bw).', 'E 03.', 'Any other chronic lung disease (cystic fibrosis, bronchopulmonary', 'dysplasia, etc) which may impair lung function.', 'E 04.', 'A subject with any history of life threatening asthma (ie, extreme', 'exacerbation that requires intubation).', 'E 05.', 'Co-morbid disease that might interfere with the evaluation of IMP', 'Total expected number of patients', 'Approximately 402 patients will be randomized in a 2:1 ratio to receive', 'dupilumab (268) or placebo (134).', 'STUDY TREATMENT(S)', 'Investigational medicinal', 'Dupilumab (SAR231893/REGN668) or matching placebo', 'product(s)', 'Formulation:', 'Dupilumab for children <30 kg bw at randomization: 150 mg/mL in pre-filled', 'syringe to deliver a once every 2 weeks (q2w) dose of 100 mg in a 0.67 mL', 'subcutaneous injection.', 'Dupilumab for children >30 kg bw at randomization: 175 mg/mL in pre-filled', 'syringe to deliver a once q2w dose of 200 mg in a 1.14 mL subcutaneous', 'injection.', 'Placebo: Matching placebo in a prefilled syringe to deliver a once q2w dose of', 'placebo in a 0.67 or 1.14 mL subcutaneous injection for children with <30 or', '>30 kg bw at randomization, respectively.', 'Route(s) of administration:', 'Subcutaneous (SC) injection', 'Dose Regimen', 'Randomized 2:1 to the following regimens:', 'Dupilumab 200 or 100 mg SC once q2w for children with bw >30 kg', 'or <30 kg, respectively.', 'Placebo SC q2w', \"After randomization, dose regimen will not be adjusted for patient's age or\", 'weight during the Randomized Treatment Period of this study.', 'Noninvestigational medicinal', 'Inhaled corticosteroid in combination with a second controller', 'products (Background Therapy)', 'medications', 'Screening Period', 'Formulation:', 'Prior to and during the Screening Period, patients must be on stable-dose', 'background therapy of medium-dose ICS with a second controller medication', '(ie, long-acting \u00df2 agonist (LABA), long acting muscarinic antagonist (LAMA),', 'leukotriene receptor antagonist (LTRA) or methylxanthines) or high-dose ICS', 'alone or high-dose ICS with second controller.', 'Property of the Sanofi Group - strictly confidential', 'Page 11', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Randomized Treatment Period', 'During this period, patients will continue taking their controller medication(s)', 'For patients experiencing deterioration of asthma during the study, the ICS', 'dose may temporarily be increased up to 4-fold (recorded as LOAC event) for', 'a maximum of 10 days, as indicated and upon recommendation of the', 'physician and/or Investigator. Treatment may then be changed to systemic', 'corticosteroids (severe exacerbation event) or revert back to the original ICS', 'dose depending on asthma symptom progression.', 'Patients may be placed on SCS at any time as clinically indicated based the', 'presence of symptoms consistent with a severe asthma exacerbation event,', \"as per the Investigator's judgment.\", 'If a patient experiences 2 or more severe asthma exacerbation events', 'anytime during the study, a permanent change (ie, step up in medium- to', 'high-dose ICS or addition of second controller for patients on high-dose ICS', 'monotherapy) on their stable-dose background controller medication may', 'occur, as indicated and upon recommendation of the physician and/or', 'Investigator.', 'Post-treatment Period', 'Upon completing the randomized treatment period, patients not continuing', 'with the 1-year long-term extension study, will continue treatment with the', 'controller medication regimen and dose used during the randomized period,', \"which could be adjusted based on medical judgment of the patients' asthma\", 'control status.', 'Reliever Medication', 'Patients may use albuterol/salbutamol or levalbuterol/levosalbutamol MDI as', 'reliever medication as needed during the study. Nebulizer solutions may be', 'used as an alternative delivery method.', 'Route(s) of administration:', 'Oral inhalation by puff inhalation with MDI (eg, ICS, ICS combination,', 'albuterol/salbutamol or levalbuterol/levosalbutamol; for other background', 'controllers according to label)', 'Dose regimen:', 'ICS: medium to high-dose in combination with a second controller', 'Reliever medication: Albuterol/salbutamol or levalbuterol/levosalbutamol: as', 'needed', 'ENDPOINT(S)', 'Primary Endpoint:', 'Annualized rate of severe exacerbation events during the 52-week', 'placebo-controlled treatment period.', 'Key Secondary Efficacy Endpoint:', 'Change from Baseline in pre-bronchodilator % predicted forced', 'expiratory volume in 1 second (FEV1) at Week 12.', 'Secondary Endpoints:', 'Efficacy', 'Change from Baseline in pre-bronchodilator % predicted forced', 'expiratory volume in 1 second (FEV1) at Weeks 2, 4, 8, 24, 36 and', '52 and other time points assessed.', 'Time to first severe exacerbation event during 52-week treatment', 'period.', 'Time to first LOAC during 52-week treatment period.', 'Property of the Sanofi Group - strictly confidential', 'Page 12', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}